Abstract 464P
Background
The frailty status of elderly Chinese breast cancer patients has not been fully assessed. The aim of this study was to assess the prevalence of frailty and pre-frailty and associated factors in elderly Chinese patients with breast cancer.
Methods
This is a prospective cross-sectional registry study. Breast cancer patients aged over 65 years were classified into robust (0 points), pre-frailty (1-2 points) and frailty (3-5 points) using the Frailty Screening Scale. The HADS, the sleep and pain subscale of the EORTC QLQ-C30 and the Charlson Comorbidity Index (CCI) were used to assess associated factors. Logistic regression model was used to analyse the factors related to frailty and pre-frailty.
Results
481 elderly breast cancer patients treated at our hospital from October 2021 to November 2022 were finally analysed. The median age was 69 years. 76.7% of patients were in early-stage. The proportions of patients receiving surgery, chemotherapy, radiotherapy and endocrine therapy were 91.1%, 56.5%, 30.1%, and 65.3%, respectively. 75 (15.6%) patients met the diagnostic criteria for frailty and 257 (53.4%) patients were in pre-frailty state. Multivariate logistic regression analysis showed that independently associated risk factors for frailty included advanced tumours, more comorbidities, anxiety, insomnia and pain (all P<0.05). The latter three factors were also independently associated with pre-frailty (all P<0.05). Age, BMI, molecular subtype (not shown) and treatment were not significantly associated with frailty and pre-frailty (all P>0.05) (Table). Table: 464P
Multivariable analysis
Robust vs pre-frailty | Robust vs frailty | |||
OR | P | OR | P | |
Age | 0.98(0.94-1.03) | 0.51 | 1.00(0.92-1.09) | 0.98 |
Stage | ||||
Early | - | - | ||
Advanced | 1.51(0.79-2.87) | 0.21 | 12.95(4.38-38.31) | <0.01 |
Surgery | 1.31(0.57-2.99) | 0.53 | 2.02(0.51-8.09) | 0.32 |
Chemotherapy | 0.93(0.56-1.52) | 0.76 | 0.59(0.26-1.36) | 0.22 |
Radiotherapy | 0.79(0.47-1.33) | 0.38 | 0.68(0.27-1.69) | 0.40 |
Endocrine therapy | 1.11(0.58-2.11) | 0.76 | 0.48(0.16-1.47) | 0.20 |
CCI | 1.17(0.98-1.41) | 0.09 | 2.07(1.39-3.08) | <0.01 |
Anxiety | 4.00(1.09-14.66) | 0.04 | 7.45(1.33-41.63) | 0.02 |
Depression | 1.12(0.45-2.77) | 0.81 | 0.52(0.12-2.22) | 0.38 |
Insomina | 1.01(1.00-1.02) | 0.01 | 1.02(1.00-1.03) | 0.01 |
Pain | 1.02(1.01-1.03) | 0.01 | 1.03(1.01-1.05) | <0.01 |
Conclusions
Frailty is not prevalent in elderly breast cancer, but most of them are in a pre-frailty state. Before making clinical decisions for these patients, it is necessary to evaluate the associated factors and to make appropriate interventions for controllable factors (such as anxiety, insomnia, comorbidities, etc.) to improve patients' tolerance and compliance with tumour treatment.
Clinical trial identification
Editorial acknowledgement
This research was funded by Medical Oncology Key Fundation of Cancer Hospital Chinese Academy of Medical Sciences (grant number CICAMS-MOMP2022007) and National Key R&D Program of China (grant number 2020YFC2004803).
Legal entity responsible for the study
P. Zhang.
Funding
Medical Oncology Key Fundation of Cancer Hospital Chinese Academy of Medical Sciences (grant number CICAMS-MOMP2022007) and National Key R&D Program of China (grant number 2020YFC2004803).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract